Learn how MAT1A helps convert methionine into S-adenosylmethionine—often shortened to SAM—and why the gene is relevant to liver-focused methylation and methionine metabolism.
A MAT1A result should be interpreted at the exact variant level. A common wellness-panel SNP, a carrier finding, and a clinically significant variant linked with methionine adenosyltransferase deficiency are not interchangeable.
MAT1A provides instructions for making the liver-focused methionine adenosyltransferase enzyme that converts methionine and ATP into S-adenosylmethionine, or SAM.
SAM is a major methyl-group donor used in reactions involving DNA, proteins, lipids, neurotransmitter-related compounds, and other molecules. After a methyl group is transferred, SAM becomes S-adenosylhomocysteine, connecting MAT1A with the wider methionine and homocysteine cycle.
MAT1A is discussed in methylation education because it helps produce the molecule that supplies methyl groups to many biological reactions.
Read SNPs and methylation and genetic variants versus mutations before interpreting a highlighted result.
The genes encode related methionine adenosyltransferase proteins, but their tissue-expression patterns, enzyme forms, and clinical contexts are not identical.
MAT1A is expressed strongly in the liver and produces the alpha-1 protein subunit. Its proteins can assemble into enzyme forms commonly called MAT I and MAT III.
MAT2A also converts methionine and ATP into SAM, but it is expressed across many tissues and encodes a different methionine adenosyltransferase protein.
The pathway is more useful when read as a cycle involving several enzymes and nutrients rather than as a single MAT1A result.
Methionine enters the pathway from dietary protein and recycled homocysteine.
The MAT1A enzyme uses methionine and ATP to produce SAM in the liver.
SAM donates methyl groups to DNA, proteins, lipids, and other compounds.
Reactions involving SAH and homocysteine continue the cycle toward remethylation or transsulfuration.
The test reports inherited DNA. Current metabolism, liver health, and blood amino-acid levels require separate assessment.
MAT1A contains many different variants. Their significance can range from benign to uncertain or clinically important.
Record the rsID or HGVS notation. Do not assume that evidence for one MAT1A variant applies to another.
Confirm which two alleles were detected and whether the report calls the result heterozygous or homozygous.
MAT1A-related hypermethioninemia can involve different inheritance patterns depending on the specific variant.
Review ClinVar classification, review status, population frequency, functional evidence, and the date of evaluation.
A wellness-panel label is not the same as a clinical classification. “Reduced,” “risk,” “slow,” or a red color may be proprietary report wording. Check the exact variant against a recognized clinical database before making a health conclusion.
MAT1A produces SAM, but several other genes help use, recycle, and redirect compounds in the wider pathway.
Depending on the panel, related genes may include genes involved in folate-dependent remethylation, vitamin B12–dependent reactions, S-adenosylhomocysteine processing, glycine methylation, transsulfuration, and choline-related remethylation.
Broader coverage provides context only when the report identifies the exact variants, explains the evidence, and distinguishes established findings from preliminary associations.
An at-home wellness panel may provide educational genotype information. It is not a replacement for metabolic testing or the state-based newborn screening and follow-up process.
In the United States, an elevated methionine finding can be detected through newborn blood-spot screening. State and territory programs choose their own panels and follow-up systems, so procedures, contacts, and included conditions can differ by location.
An out-of-range newborn result does not confirm a diagnosis, but it should be followed promptly through the baby’s healthcare provider and state program. Follow-up may involve blood or urine testing and clinical genetic testing.
For an adult wellness result, begin with the test provider for report mechanics. Questions about elevated methionine, liver function, or symptoms may require a local clinician and conventional laboratory testing. Questions about a rare or clinically classified variant may be better directed to a genetic counselor or metabolic genetics team.
For parents: Check the official newborn-screening program for your state rather than relying on a consumer genetics website for screening requirements or follow-up instructions.
Trustworthy interpretation begins with the official gene record and then moves to the exact variant, classification, review status, population frequency, functional studies, inheritance evidence, and clinical context.
Direct answers about MAT1A, SAM production, MAT2A, methionine, hypermethioninemia, and responsible result interpretation.
MAT1A provides instructions for a liver-focused methionine adenosyltransferase enzyme. The enzyme converts methionine and ATP into S-adenosylmethionine, or SAM.
SAM supplies methyl groups to many biological reactions. MAT1A helps produce SAM in the liver, which places it near the beginning of the methionine and methyl-transfer cycle.
No. Both genes encode proteins that help produce SAM, but MAT1A is strongly liver-focused and MAT2A is expressed more broadly across tissues. A result in one gene should not be interpreted as a result in the other.
No. Diagnosis depends on the exact variant, inheritance pattern, clinical context, and appropriate biochemical and genetic testing. A consumer wellness result is not sufficient by itself.
No. A genetic report identifies inherited DNA at a tested location. It does not directly measure current methionine, SAM, SAH, homocysteine, or liver enzyme activity.
Not necessarily. The meaning depends on the exact variant because MAT1A-related findings can involve different inheritance patterns. Review the variant classification and discuss a clinically significant finding with a genetics professional.
Do not restrict protein or methionine based only on a consumer genetic report. Dietary treatment is condition-specific and should be supervised by an appropriate metabolic healthcare team.
Newborn screening may identify elevated methionine, which can lead to follow-up for conditions involving MAT1A or other genes. Screening panels and processes vary by state, and an out-of-range screen requires confirmatory follow-up.
A primary care clinician can assess symptoms and conventional testing. A genetic counselor, medical geneticist, or metabolic specialist may be appropriate for a rare, pathogenic, or newborn-screening-related finding. Availability varies by location and state-licensed telehealth rules.
Review the exact genes and variants, laboratory method, report detail, privacy information, price, sample-return process, and testing limitations. Do not assume that including MAT1A means the test evaluates every clinically important MAT1A variant.
Confirm the exact variant, genotype, evidence, inheritance context, panel coverage, and report limitations before deciding whether the finding is relevant to your goals.
Educational genetic information should support better questions—not replace amino-acid testing, liver assessment, newborn-screening follow-up, or individual medical care.
